UCB establishes permanent research chair at Brigham and Women’s Hospital
Pharmaceutical company UCB has endowed a chair at Brigham and Women’s Hospital to focus on pharmacoepidemiology and real-world evidence.
UCB has established the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women’s Hospital. The endowment is designed to advance research into pharmacoepidemiology, specifically focusing on how real-world data can be utilized to assess the safety and efficacy of therapeutic interventions.
The initiative will be led by Sebastian Schneeweiss, an expert in the field of pharmacoepidemiology. His research centers on improving medication safety and value by analyzing how treatments perform in large patient populations outside of conventional clinical trials.
This move signifies a commitment to integrating real-world evidence into the pharmaceutical lifecycle. By permanently endowing this position, UCB aims to support continuous methodological advancement in drug evaluation, providing a clearer understanding of how medications impact patient outcomes in standard clinical settings.